WallStSmart

Edwards Lifesciences Corp (EW)vsRapid Micro Biosystems Inc (RPID)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 17965% more annual revenue ($6.07B vs $33.59M). EW leads profitability with a 17.7% profit margin vs -140.3%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

RPID

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -5.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for RPID.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

RPID1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37.3%10/10

Revenue surging 37.3% year-over-year

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

RPID4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$104.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-86.8%2/10

ROE of -86.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : RPID

The strongest argument for RPID centers on Revenue Growth. Revenue growth of 37.3% demonstrates continued momentum.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : RPID

The primary concerns for RPID are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

EW profiles as a mature stock while RPID is a hypergrowth play — different risk/reward profiles.

RPID carries more volatility with a beta of 1.39 — expect wider price swings.

RPID is growing revenue faster at 37.3% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 33/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Rapid Micro Biosystems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rapid Micro Biosystems Inc is an innovative biotechnology company focused on revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated growth-based microbial detection technologies, the firm significantly improves the precision and efficiency of microbial testing, ensuring high product quality and regulatory compliance. With an increasing demand for rapid, reliable quality control solutions in regulated environments, Rapid Micro is well-positioned to meet these urgent market needs and lead the evolution of microbiological testing methodologies.

Visit Website →

Want to dig deeper into these stocks?